Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 12,090 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Travere Therapeutics Trading Down 1.9 %

NASDAQ TVTX opened at $18.70 on Thursday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The business has a fifty day simple moving average of $16.95 and a 200 day simple moving average of $11.61. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $20.33. The firm has a market capitalization of $1.46 billion, a P/E ratio of -4.16 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last announced its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The company had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same quarter in the prior year, the company posted ($1.17) earnings per share. The firm’s revenue for the quarter was up 69.6% on a year-over-year basis. On average, analysts predict that Travere Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Guggenheim boosted their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Piper Sandler boosted their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Bank of America raised their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright dropped their target price on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Finally, Wedbush lifted their price target on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.62.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its holdings in Travere Therapeutics by 79.2% during the first quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock worth $1,423,000 after acquiring an additional 81,611 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Travere Therapeutics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after buying an additional 1,557 shares during the last quarter. Vanguard Group Inc. grew its position in Travere Therapeutics by 13.6% during the first quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company’s stock valued at $48,310,000 after buying an additional 750,686 shares during the period. Acadian Asset Management LLC purchased a new stake in Travere Therapeutics during the first quarter worth about $368,000. Finally, EntryPoint Capital LLC bought a new stake in Travere Therapeutics in the first quarter worth about $32,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.